Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013
LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009
Ceramide-1-phosphate decreases allergic airway inflammation, remodeling and hyperresponsiveness by inhibition of phosphorilation of NF-kappa B, Akt, MAPK p-38 in dendritic cells Source: Annual Congress 2010 - Models of airways disease Year: 2010
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids Source: Eur Respir J 2011; 37: 933-942 Year: 2011
The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via activation of protein phosphatase PP2A Source: Annual Congress 2011 - Phagocytes and dendritic cells Year: 2011
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Increased activation of p38 MAPK in COPD Source: Eur Respir J 2008; 31: 62-69 Year: 2008
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Ventilation-induced activation of the mitogen-activated protein kinase pathway Source: Eur Respir J 2002; 20: 946-956 Year: 2002
c-Jun N-terminal kinase-dependent mechanisms in respiratory disease Source: Eur Respir J 2006; 28: 651-661 Year: 2006
Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010
Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013
N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells Source: Eur Respir J 2003; 22: 43-49 Year: 2003
Inhibition of P38 kinase does not reduce production of TNF-alpha from airway cells in COPD Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007